title: Respiratory syncytial virus immunoprophylaxis in an urban population: a comparison of delivery strategies and outcomes.
abstract: Prophylaxis with palivizumab has been shown to decrease hospitalizations in at-risk infants. Compliance was higher with a home-based rather than a clinic-based system and was associated with decreased hospitalizations and unscheduled medical visits. Home-based delivery of respiratory syncytial virus prophylaxis may be more efficacious in preventing disease through increased compliance and decreased exposure of the high-risk infant to the clinic environment.
authors.affiliation: Division of Neonatology, Department of Pediatrics, Queens Hospital Center, Jamaica, NY 11432, USA. handi@nychhc.org
authors.forename: Ivan L
authors.initials: IL
authors.lastname: Hand
authors.forename: Lawrence
authors.initials: L
authors.lastname: Noble
authors.forename: Donna
authors.initials: D
authors.lastname: Geiss
authors.forename: Alan
authors.initials: A
authors.lastname: Shotkin
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D000069455:Palivizumab; D018357:Respiratory Syncytial Virus Infections / Q000517:prevention & control*; D012189:Retrospective Studies; D012307:Risk Factors; D014505:Urban Population
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab